Varicella zoster vaccine, live, attenuated; minimum of 19,400 PFU/0.65mL dose; pwd for SC inj after reconstitution; contains porcine gelatin, neomycin and bovine serum (trace); preservative-free.
Varicella zoster vaccine recombinant, adjuvanted; susp for IM inj after reconstitution (contains 50mcg of recombinant glycoprotein E antigen, 50mcg of monophosphoryl lipid A, and 50mcg of QS-21); per 0.5mL; preservative-free.
The herpes zoster vaccine is effective in protecting older adults against shingles, even if they later undergo chemotherapy, according to new research.
Investigators assessed the risk for herpes zoster and provided recommendations regarding treatment in patients with psoriasis.
According to the results of a recent study, rates of physician recommendation, administration, and referral related to vaccination differed in adult patients depending on the type of insurance they had (commercial or Medicare).
The zoster vaccine is safe and well tolerated in older adults, despite an increased risk of allergic reaction in the days following vaccination.
Incremental cost-effectiveness ratio varied from $10,000 to $47,000 per QALY for RZV versus no vaccine
Depressed elderly patients display a diminished varicella zoster virus (VZV)-specific immune response after vaccination with the herpes zoster vaccine compared with non-depressed patients, but antidepressant medication helps to normalize this response.
Vaccines represent the single most important medical advancement of the 20th century. Yet vaccines now available to prevent polio, measles, influenza, varicella, and zoster remain underutilized, presenters told IDWeek 2012 attendees.